All lobbying filings

Desimone Consulting, LLC

Desimone Consulting, LLC filed a Q1 report for Pharmaceutical Research and Manufacturers of America (PHRMA) on April 14, 2026, reporting $30,000 in lobbying income.

Lobbying for Pharmaceutical Research and Manufacturers of America (PHRMA) · trade group representing U.S. pharmaceutical research and biotechnology companies

As filed: DESIMONE CONSULTING, LLC for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA).

All filings by Desimone Consulting, LLC · Everything Pharmaceutical Research and Manufacturers of America (PHRMA) has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 14, 2026

Income

$30,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Pharmacy

Issues related to patient access and pricing. Issues related to policy changes to Medicare Part D. Issues related to 340B reform. Issues related to Most Favored Nation (MFN) policy. Issues related to PBM reform; H.R.4317, PBM Reform Act of 2025; S.3345, PBM Price Transparency and Accountability Act; H.R.7148, Making further consolidated appropriations for the fiscal year ending September 30, 2026, and for other purposes (P.L.119-75).

Bills named in this filing 3

H.R. 4317
PBM Reform Act of 2025
S. 3345
PBM Price Transparency and Accountability Act
H.R. 7148
Consolidated Appropriations Act, 2026

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.